The most encouraging results, in patients with advanced DTC and DeDTC unresponsive to radioiodine therapy and MTC, were obtained with the targeted kinase inhibitors with an intrinsic activity against VEGFR and cross activity against RET kinases, such as pazopanib, sorafenib, motesanib, sunitib and vandetanib. Here, KDR is linked to medullary thyroid gland carcinoma.